StockWatch
·

J.G.Chemicals Ltd Q2 FY27 Results

JGCHEMQ2 FY27 Results
Filing
Result:Very Good· Market: Flat#Broad based#Margin expansion#Record quarter

Outlook: Very Optimistic · Guidance: Maintained

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue361.0114.4%63.9%
Total Income361.5813.6%61.3%
Expenditure324.3414.4%59.1%
PBT37.246.5%83.0%
Net Profit27.957.0%85.9%
OPM10.55%0.07pp2.40pp
NPM7.73%0.47pp1.02pp
EPS6.816.4%85.6%
View full financials

Revenue +64% YoY and PAT +86% YoY (outpacing revenue) with clean adjusted profit, OPM expanding ~240bps to 10.55% on lower material costs, and revenue at a 6-quarter high — a standout for the specialty chemicals sector with no one-off support.

JGCHEM · Q2 FY-2027 · THE VERDICT

Record Growth, Reaffirmed Guidance — The Dahej Wager Begins

J.G. Chemicals delivered 64% revenue growth and 86% PAT growth, hitting every near-term target. Yet management maintained, rather than raised, its three-year guidance. The gap between execution and outlook is the story — and the market, down 17% from ATH, is skeptical.

06 Nov 2026 · 6 min read
Revenue (Q2 FY-2027)

₹361.0 Cr

+63.9% YoY, +14.4% QoQ

PAT (Q2 FY-2027)

₹28.0 Cr

+85.9% YoY, +7.0% QoQ

EBITDA margin

10.71%

vs 11.07% Q1; tracking 11-12% Phase 1 target

Capacity utilization

>80%

October highest production ever

J.G. Chemicals delivered its strongest quarter on record — ₹361 Cr revenue, ₹28 Cr PAT — and is executing against every near-term commitment. Yet the real story is not the headline numbers. It's the gap between what management delivered and what it chose not to promise: despite 64% YoY revenue growth and 86% PAT growth, management reaffirmed its medium-term guidance rather than raised it. This is the tension that defines the quarter.

What the numbers say about management's claims

All major claims cross-checked against the result and Q&A

Best-ever quarterly performance, surpassing Q1

Q2 revenue ₹361.01 Cr (vs ₹316 Cr Q1); PAT ₹27.95 Cr (vs ₹26.1 Cr Q1)

Supported

Dahej Phase 1 commissioning next month with trial runs

Trial runs confirmed for December; consistent with facility nearing completion on track

Supported (slipped from November, minor)

Confident in 14-15% EBITDA margins within 3 years

H1 FY27 EBITDA margin 11.07%; Q2 10.71%. Trajectory aligns with phased capacity and product mix shift to non-rubber (18% → 30%)

Supported (credible path)

Strong demand across OEM/tire/automotive sector

64% YoY revenue growth; October highest production ever; volume growth mid-teens confirmed in Q&A

Supported (exceeds mid-teen guidance)

Naidupeta 5K MTPA brownfield Q3 target, mid-January spillover acceptable

Management clarified Q3 target for ramp-up with mid-January full commissioning; timeline reasonable for brownfield

Supported (reasonable timeline)

What changed on this call

Dahej Phase 1 commissioning confirmed for December (vs. November prior guidance) — trial runs next month on track. FY27 revenue guidance now explicit: >₹1,200 Cr (vs. ₹361 Cr Q2, ₹677 Cr H1) — reaffirmed, not raised. This is significant: the company is doubling revenue every three years (₹600 Cr FY24 → ₹1,200+ Cr FY27), and this quarter's 64% growth is the deliverable of that plan, not a surprise. Non-rubber applications ramp clarified: 18% today → 30% target by FY29 — a new milestone for tracking margin expansion via product mix. EBITDA margin target 14-15% by FY29 reaffirmed on consolidated basis. All guidance held, none raised.

Why management isn't raising sights despite record execution

This is the conversation beneath the conversation. Management is laser-focused on two sequential events: (1) Dahej Phase 1 achieving customer qualifications and ramp-up (FY28 target 60-70% utilization), and (2) specialty product mix hitting 30% of revenue to unlock the 14-15% EBITDA margin. Until both are proven, guidance stays locked. The company is also carrying elevated working capital — inventory expanded ₹92→154 Cr in H1, receivables ₹177→207 Cr — and management acknowledged 90-100 day cycles are inherent to this growth phase. Translation: cash flow is good but capital-intensive; no room for surprises yet.

Our working capital intensity is about 90 to 100 days of working capital days. And even if we expect the run rate to continue where we are today for the next 2 quarters, our cash position would definitely improve. And as a company, we feel that any company which is in a high-growth phase, the cash flow from operations after working capital changes could be negative.

The bull-bear ledger

  • India's largest zinc oxide recycler (77K MTPA capacity) well-positioned to capture market share from fragmented competitors in consolidation wave

  • Volume growth corroborated: 64% YoY beats mid-teen guidance; October highest-ever production

  • Margin trajectory on track: H1 11.07% EBITDA margin tracking toward 11-12% Phase 1 guidance

  • Strong balance sheet: ₹63 Cr net cash, no external funding needed for Phase 2 capex even if growth maintained

  • Working capital build evident: Inventory ₹92→154 Cr, receivables ₹177→207 Cr in H1; 90-100 day cycle material if growth accelerates

  • Dahej Phase 1 ramp-up is sequential: customer qualifications → production ramp → utilization targets; delays could push FY29 targets to FY30+

  • Margin compression Q1→Q2: EBITDA margin 11.07%→10.71% (LME zinc lag explained; creates quarterly volatility)

  • New ventures still nascent: Recycled rubber (JG TUR), battery zinc oxide in pilot trials; 2-3 year commercialization timelines vague on quantified milestones

Risks, ranked by how much they should concern a holder

The hurdles to FY29 guidance

Dahej Phase 1 customer qualification and ramp-up execution

15K MTPA capacity must achieve customer qualifications and production ramp over 2-3 quarters to hit FY28 60-70% utilization target. Delays could push 14-15% EBITDA realization to FY30; would pressure FY28-29 guidance.

Medium

Zinc commodity price swings and LME lag volatility

Zinc oxide sold at LME-linked pricing; Q2 margin compression (11.07%→10.71%) driven by procurement lag. Sustained deflation or lag spikes could compress per-ton margins and create quarterly volatility.

Medium

Working capital intensity and cash flow timing

90-100 day cycle at ₹1,200+ Cr FY27 revenue run rate means ~₹300+ Cr tied up in inventory/receivables. If growth accelerates beyond plan or collections slip, could strain cash despite ₹63 Cr net cash buffer.

Medium

New product commercialization delays (recycled rubber, battery zinc oxide)

Non-rubber apps target 18%→30% by FY29 depends on JG TUR scaling and battery zinc oxide customer adoption. If adoption slower than 2-3 year timelines, specialty mix shift and margin lift could slip 1-2 years.

Medium

FII/institutional ownership decline and market skepticism

FII ownership down from 6.05% (FY25 Q4) to 3.21% (FY27 Q1); DII also trimmed. Stock down 17% from ATH despite record results. Suggests institutions pricing in execution risk, valuation reset, or rotation away from growth plays.

Medium-to-Low (market signal, not fundamental)

How the street is positioned

J.G. Chemicals trades at ₹575.75 as of 2026-11-05, down 17.15% from its all-time high of ₹694.9 but up 92.95% from its 52-week low of ₹298.4. The stock sits below its 20-day SMA (₹599.04) and 50-day SMA (₹607.12), above its 200-day SMA (₹461.45). RSI is 45.4 — neutral.

Post-result price action: The 17% drawdown from ATH despite delivering record results and beating volume guidance is the market's own verdict. This is not a selloff driven by misses; it's skepticism baked into a re-rating. The market is pricing in either: (1) execution risk on Dahej Phase 1 customer ramp, (2) doubt about specialty product mix and new ventures delivering on timeline, (3) working capital/cash flow concerns, or (4) valuation reset at prior ATH levels. None of these are fundamental surprises — they're all discussed on the call — but institutions are hedging them.

Institutional flows: FII ownership declined from 6.05% (FY25 Q4) to 3.21% (FY27 Q1) — a 284bp drop. DII also trimmed from 3.49% to 3.00%. Promoter ownership stable at 70.99%. This ownership shift is significant: large institutions are exiting or reducing exposure despite strong execution, reinforcing the view that the market is pricing in execution or valuation risk, not fundamentals.

Bulk/block deals (August 2026): Junomoneta Finsol Private Limited, HRTI Private Limited, and other financial entities rotated ₹620–₹656 range. No clear promoter insider selling. The bulk deal activity suggests some players see value at current levels, but the lack of sustained accumulation and the FII exit pattern suggests consensus skepticism.

What to watch next
  • 1 · Dahej Phase 1 trial runs and customer qualifications (December 2026 onwards)

    Q3 FY27 updates on production run-rate achieved, customer order visibility, and ramp trajectory for FY28. This is the de-risker for the long-term margin target. Key metric: are qualifications tracking on schedule, or are spillovers into Q4 FY27 appearing?

  • 2 · Naidupeta 5K MTPA brownfield commissioning (Q3 FY27 / January 2027 ramp-up)

    Confirm timeline slip from Q3 to mid-January is immaterial. Monitor whether new capacity is adding to revenue and utilization by Q4 FY27 / Q1 FY28.

  • 3 · Non-rubber applications revenue contribution trajectory (Q3 / Q4 tracking)

    Confirm 18%→30% shift is credible. If specialty product mix is stalling, margin expansion thesis to 14-15% FY29 gets pushed out. This is the linchpin of the guidance.

J.G. Chemicals is delivering on what it promised — record growth, capacity on schedule, margins on track. But the stock's 17% drawdown from ATH despite record results is not a market accident; it's the repricing of a steady-state expansion plan against expectations of a surprise inflection. The company's decision to reaffirm, rather than raise, medium-term guidance signals confidence in the long-term thesis but realism about execution risk and commodity swings.

The honest read is neither bull nor bear; it's pragmatic. The Dahej Phase 1 de-risker comes in Q3-Q4 FY27. If utilization ramps to 60-70% on schedule and specialty product mix flows toward 30%, the 14-15% FY29 EBITDA target is credible, and the ₹575 price will look cheap. If delays emerge or mix shifts slow, the drawdown could extend. The number to track from here is Dahej Phase 1 utilization and the trajectory to FY28 guidance — everything else flows from that execution.

Informational and educational content only. Not investment advice.